Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma

NCT07018570 is registered in ClinicalTrials.gov with National Cancer Center Hospital East as lead sponsor.

NCT NCT07018570
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07018570 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma
Lead sponsor
National Cancer Center Hospital East
Phase
Phase 2
Overall status
Recruiting
Start date
July 24, 2025
Completion date
June 30, 2031
Enrollment
26 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastroesophageal junction (gej) adenocarcinoma